(1) Treatments for @entity28 are disappointing. None has yet shown an effect on morbidity and mortality. Non drug treatments are poorly assessed. Stable long-term @entity353 necessitates long-term management. (2) @entity350 , a gastrointestinal lipase inhibitor, is indicated, in combination with a low-calorie diet, for the management of @entity28 . (3) The assessment file is rather bulky and methodologically sound, at least in terms of the " @entity353 " end point. (4) During medium-term trials (12-24 months), @entity350 administered at a dose of 120 mg three times a day and combined with dietary intervention had a moderate positive impact on body weight (-3.5 kg on average). (5) No longer-term trials have been done. (6) It is not known whether this drug affects morbidity and mortality linked to @entity28 . (7) In clinical trials there was an increase in the frequency of @entity0 among @entity1 treated with @entity350 . This potential risk is currently being assessed in a specific trial. (8) Gastrointestinal adverse effects are frequent. (9) Treatment is costly.

XXXX : new preparation. No hurry . . .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity350 :: ('MESH:C055122', 'Chemical') :: ['Orlistat', 'orlistat'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity353 :: ('MESH:D015431', 'Disease') :: ['weight loss'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity']
@entity350 :: (MESH:C055122,Chemical) :: ['Orlistat']
